Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 533 of 6351
-
ALS drug already approved for some may help others
Disease control Recruiting nowThe goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are: * Does tofersen lower the level…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New biosimilar aims to match leading melanoma treatment
Disease control Recruiting nowThis is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma
Phase 3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could stem cells restore erectile function in diabetic men?
Disease control Recruiting nowThe goal of this prospective randomized controlled clinical study is to evaluate the effectiveness and safety of intracavernosal injections of umbilical cord-derived mesenchymal stem cells (MSCs) and umbilical cord-derived MSC-derived exosomes in men aged 25 to 75 years with diab…
Phase 2/3 • Sponsor: Ankara City Hospital Bilkent • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cocktail aims to shrink rectal tumors and save the sphincter
Disease control Not yet recruitingThe goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with pMMR locally advanced low rectal cancer. It will a…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for Hard-to-Treat breast cancer: Two-Drug cocktail shows promise
Disease control Recruiting nowThis is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any programmed cell death-ligand 1 (PD-L1) status metastatic,…
Phase 1/2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo aims to stop liver cancer from coming back
Disease control Not yet recruitingThis study is a prospective, randomized controlled, phase II trial evaluating the efficacy and safety of neoadjuvant therapy with Sintilimab combined with SBRT in patients with resectable hepatocellular carcinoma. After meeting the inclusion and exclusion criteria and providing …
Phase 2 • Sponsor: Lei ZHAO • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with large B-cell lymphoma (LBCL) that has come back after …
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
Disease control Recruiting nowAn open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
Early phase 1 • Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
CAR-T therapy takes on tough blood disorder in early trial
Disease control Not yet recruitingThis is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a new injection help people shed significant weight?
Disease control OngoingThis study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants. A total of 125 participants were enrolled in the study. …
Phase 2 • Sponsor: Shanghai Minwei Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill could ease stiffness and pain for ankylosing spondylitis patients
Disease control Recruiting nowThis clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Phase 3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cell therapy combo targets tough stomach cancers
Disease control Recruiting nowThe goal of this clinical trial is to learn the safety of tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell in treating advanced gastric cancer in adults. It will also learn if the combined treatment works to treat advanced gastric cancer. The main questio…
Phase 1 • Sponsor: Jia Wei • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could umbilical cord stem cells help failing hearts?
Disease control Recruiting nowB2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated…
Phase 1/2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo aims to supercharge immune attack on lymphoma
Disease control Recruiting nowTargeted therapy against the CD30 molecule has achieved some progress in CD30-positive Hodgkin lymphoma, but its efficacy remains unsatisfactory. Previous studies have demonstrated that N-glycan modifications in the extracellular domain of target proteins can disrupt immune synap…
Phase 1/2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cocktail of drugs takes on rare brain cancer
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy and safety of a four-drug combination regimen as first-line treatment for adults aged 18 years and older with newly diagnosed primary central nervous system lymphoma (PCNSL). The main questions it aims to answer are: Do…
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cocktail therapy targets tough liver cancer with blood clot
Disease control Recruiting nowThe goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver cancer patients with VP3/4 portal vein tumor thrombu…
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for sarcoma patients: novel drug combo enters human trials
Disease control Recruiting nowWhat is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and soft tissue sarcomas whose disease has progressed …
Phase 2 • Sponsor: Shanghai 6th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Ancient herbs meet modern medicine in new fertility trial for women with low egg reserve
Disease control Not yet recruitingThis study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen ("Xiehe DOR Bushen Tongzhi Formula" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulati…
Phase 3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New obesity drug HRS9531 takes on semaglutide in major trial
Disease control OngoingThis study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
Phase 3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug cocktail aims to control follicular lymphoma without chemo
Disease control Recruiting nowThis study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC